Allogene Therapeutics, Inc.

US$1.04As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ALLOHealthcare
Country USA
PE (Fwd) •••
TSR 8Y CAGR (32.38%)
Div yield —
ROE (49.29%)
Biotechnology
Beta (5Y) 0.78
PE TTM —
TSR TTM (16.13%)
Mkt cap US$360.3M
ROIC (27.82%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.23
17.98%
(88.58%)
Hold 4|10|1|1|0
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.02
0.02
0.02
0.02
34.20%
29.65%
18.80%
8.32%
Revenue$M
20.55
20.14
20.79
20.89
13.95%
5.74%
4.83%
6.94%
Peers (US$360.3M)
Cap (US$)
PE
357.0M
—
Capital
TTM
5Y
10Y
Leveragex
0.263
(0.104)
(0.110)
EBIT/Intx
0.692
0.337
0.263
Own earn%
(18.56)
(64.63)
(45.07)
Sh yield%
51.32
45.98
43.00
Owners
Insiders/Inst%
13.47
28.60
Short interest%
2.18
SBC / revenue%
4.16
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
18
Op margin range%
1–11
$1 testx
—
Incr. ROIC%
8